Clinical Trial Detail

NCT ID NCT02750215
Title A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Capmatinib

Age Groups: adult senior

Additional content available in CKB BOOST